STIMAIRE
StimAire, a US-based injectable neuromodulation company, focusing initially on obstructive sleep apnea.
STIMAIRE
Industry:
Health Care Medical Device
Founded:
2017-09-01
Address:
Tucson, Arizona, United States
Country:
United States
Website Url:
http://www.stimaire.com
Total Employee:
1+
Status:
Active
Contact:
1-520-360-0823
Total Funding:
2.67 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon WordPress Gravatar Profiles Jetpack Site Accelerator Comodo SSL Wordpress OEmbed EssentialSSL Comodo Essential SSL WildCard
Similar Organizations
P3 Health Partners
P3 Health Partners is a patient-centered, physician-led and population health-focused healthcare company.
Current Advisors List
Board_member
2019-01-01
Board_member
2019-01-01
Board_member
2017-01-01
Board_member
2019-01-01
Board_member
2019-01-01
Current Employees Featured
Tarek Makansi Founder and CTO @ StimAire
Founder and CTO
2017-10-01
Arthur Rascon Chief Operating Officer @ StimAire
Chief Operating Officer
2024-04-01
Fiona Bailey Respiratory Neurophysiologist @ StimAire
Respiratory Neurophysiologist
2019-01-01
Abhay Sanan Chief Medical Officer @ StimAire
Chief Medical Officer
2019-01-01
Robert Dean Chief Clinical Officer @ StimAire
Chief Clinical Officer
2020-01-01
Andrew Fuglevand Neurophysiologist @ StimAire
Neurophysiologist
2018-01-01
Founder
Investors List
Sonoran Mavericks
Sonoran Mavericks investment in Series A - StimAire
Desert Angels
Desert Angels investment in Series A - StimAire
UAVenture Capital
UAVenture Capital investment in Series A - StimAire
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-22 | StimAire Announces the Appointment of Arthur Rascon as Chief Operating Officer |
Official Site Inspections
http://www.stimaire.com Semrush global rank: 4.38 M Semrush visits lastest month: 2.24 K
- Host name: 192.0.78.242
- IP address: 192.0.78.242
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
More informations about "StimAire"
StimAire | New Sleep Apnea Treatment Device
StimAire is rapidly moving toward product launch with FDA Breakthrough Device Designation. This designation is a formal identification by the U.S. FDA that a “medical device in development should be expedited for patient access …See details»
About Us | StimAire Sleep Apnea Device
Learn more about the company and team behind the StimAire injectable sleep apnea treatment device. Skip to content. Toggle Navigation. Our Company; News; Contact us. Our Company …See details»
StimAire - Crunchbase Company Profile & Funding
When was the last funding round for StimAire? StimAire closed its last funding round on Nov 18, 2019 from a Series A round. Who are StimAire 's competitors? Alternatives and possible competitors to StimAire may include P3 Health …See details»
StimAire Company Profile 2025: Valuation, Funding
StimAire General Information Description. Developer of an injectable neuromodulation device designed to create a patient-friendly alternative for healthy sleep. The company's technology also has the potential to treat …See details»
STIMAIRE, INC. Company Profile | Tucson, AZ - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for STIMAIRE, INC. of Tucson, AZ. Get the latest business insights from Dun & Bradstreet.See details»
StimAire - Products, Competitors, Financials, Employees, …
StimAire recently completed its first-in-human study of its injectable stimulator for OSA. StimAire is a portfolio company of University Associates Venture Capital. Jul 22, 2024. StimAire …See details»
StimAire - Overview, News & Similar companies | ZoomInfo.com
Oct 11, 2023 StimAire has invented a revolutionary neuromodulation platform that can be injected through a needle in a doctor's office in under 15 minutes. Our first clinical target is …See details»
StimAire Company Profile | Management and Employees List
StimAire Profile and History. StimAire has invented a revolutionary neuromodulation platform that can be injected through a needle in a doctor's office in under 15 minutes. Our first clinical …See details»
StimAire - Contacts, Employees, Board Members, Advisors & Alumni
Organization. StimAire . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... StimAire has 5 board members and …See details»
StimAire - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Nov 18, 2019: Series A - …See details»
StimAire granted Breakthrough Device Designation
The StimAire device is intended to be used by patients who have been confirmed to fail, not tolerate, or refuse OSA treatment with Positive Airway Pressure. The FDA has granted …See details»
Neurostimulator Developer Appoints Industry Veteran as COO
Jul 29, 2024 New Leadership: StimAire has appointed an industry veteran with over 20 years of experience as COO to drive the development of its injectable neurostimulator for OSA. …See details»
StimAire - UA Venture Capital
No CPAP. No surgery. Just restful sleep. StimAire has invented a revolutionary sleep apnea treatment that utilizes a neuromodulation platform that can be injected through a needle in a …See details»
StimAire - Raised $1.56M Funding from 1 investor - Tracxn
Jan 6, 2025 StimAire has raised a total funding of $1.56M over 1 round from 1 investor. Investor includes UAVenture Capital Fund. Their latest funding round was of $1.56M on Nov 26, 2019 . …See details»
StimAire completes its first-in-human clinical trial
TUCSON, Ariz., Oct. 11, 2023 -- Paradigm-shifting neuromodulation company, StimAire, has completed its first clinical trial in Australia. The first-in-human study tested a tiny injectable …See details»
Venture Capital Invests in Non-surgical Neurostimulator for …
Nov 25, 2019 UAVenture Capital Fund (UAVC), a venture capital fund dedicated to the commercialization of University of Arizona discoveries, products, technologies, and services, …See details»
StimAire Receives Investment - VC News Daily
StimAire has developed a unique and innovative solution that will provide restful sleep and OSA prevention for countless apnea sufferers," stated Fletcher J. McCusker, UAVenture Capital …See details»
StimAire concludes injectable stimulator study for OSA
Oct 12, 2023 StimAire chief clinical officer Robert Dean said: “After developing this injection procedure for StimAire at the University of Arizona College of Medicine, I was delighted to see …See details»
News | StimAire Sleep Apnea Treatment
Get the latest updates on StimAire's groundbreaking injectable sleep apnea treatment device. Skip to content. Toggle Navigation. Our Company; News; Contact us. News SA_Admin 2024 …See details»
Injectable Neurostimulator for OSA Meets Endpoints in Clinical Trial
Oct 12, 2023 Fletcher McCusker, managing director of UAVenture Capital, StimAire’s lead investor, adds in a release, “Comparable devices have to be surgically implanted. The …See details»